What's NextMy take. Things begin to swing in a good direction in a permanent way in May and maybe before.
ONC waits for ADC outcomes to evolve and primary investigators of ADC treatments to report results at conference. ONCs planned review by key performance leaders can only occur at this moment when updated ADC data and Bracelet data are available for contrast.
Once the key performance leaders review is complete, ONC can define the target Breast Cancer patient population. We know this became an issue for them last year after Bracelet data published. I think ADC result will be reported at April's AACR meeting? Apologies if not.
Will pela target the entire HER2- population or will it target the population coming off ADC treatments. That is the question!
ONC can and will file for a phase 3 application with this clarity.
ONC is a breast cancer company! Potential risked revenues are so much greater than other opportunities. The population is so much larger. And Pela is administered with less expensive drugs not ICIs.
The market will respond in spades like it started to last year before getting derailed. The market awaits application and launch of the phase 3 breast cancer trial.